Furthermore, increased protein levels of the pro-apoptotic p53 upregulated modulator of apoptosis (PUMA) and decreased protein levels of BCL-2, p-AKT and p-ERK levels were observed upon bemcentinib treatment of AML cells [12]. The gene discussed is AKT1; the disease is acute myeloid leukemia.